Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma

Cancer Science

Volumn 100, Issue 2, 2009, Pages 225-232

  Yoneda, Mitsuhiro ^a   Suzuki, Toru ^a   Nakamura, Takahisa ^a,d   Ajima, Rieko ^a,c,e   Yoshida, Yutaka ^a,f   Kakuta, Shigeru ^a   Sudo, Katsuko ^a,g   Iwakura, Yoichiro ^a   Shibutani, Makoto ^b   Mitsumori, Kunitoshi ^b   Yokota, Jun ^c   Yamamoto, Tadashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABUNDANT IN NEUROEPITHELIUM AREA PROTEIN; GELATINASE A; GENE PRODUCT; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME REPRESSION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL PROLIFERATION; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NIH 3T3 CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 58549084814     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01030.x     Document Type: Article

References (43)

1. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci 2004; 95: 197-204.
2. Yoshida Y, Matsuda S, Ikematsu N et al. ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system. Oncogene 1998; 16: 2687-93.
3. Ikematsu N, Yoshida Y, Kawamura-Tsuzuku J et al. Tob2, a novel antiproliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases. Oncogene 1999; 18: 7432-41.
4. Guardavaccaro D, Corrente G, Covone F et al. Arrest of G (1) -S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 2000; 20: 1797-815.
5. Maekawa M, Nishida E, Tanoue T. Identification of the anti-proliferative protein Tob as a MAPK substrate. J Biol Chem 2002; 277: 37783-7.
6. Suzuki T, Kawamura-Tsuzuku J, Ajima R, Nakamura T, Yoshida Y, Yamamoto T. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev 2002; 16: 1356-70.
7. Yoshida Y, Nakamura T, Komoda M et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev 2003; 17: 1201-6.
8. Iwanaga K, Sueoka N, Sato A et al. Alteration of expression or phosphorylation status of Tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett 2003; 202: 71-9.
9. Ito Y, Suzuki T, Yoshida H et al. Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett 2005; 220: 237-42.
10. Kawakubo H, Carey JL, Brachtel E et al. Expression of the NF-κB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 2004; 23: 8310-9.
11. Struckmann K, Schraml P, Simon R et al. Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res 2004; 64: 1632-8.
12. Horai R, Asano M, Sudo K et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998; 187: 1463-75.
13. Kitamura T, Koshino Y, Shibata F et al. Retrovirus-mediated gene transfer and expression cloning: Powerful tools in functional genomics. Exp Hematol 2003; 31: 1007-14.
14. Kohno T, Kawanishi M, Matsuda S et al. Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma. Genes Chromosomes Cancer 1998; 21: 236-43.
15. Nagayama K, Kohno T, Sato M, Arai Y, Minna JD, Yokota J. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 2007; 46: 1000-10.
16. Ten Have-Opbroek AA, Benfield JR, van Krieken JH, Dijkman JH. The alveolar type II cell is a pluripotential stem cell in the genesis of human adenocarcinomas and squamous cell carcinomas. Histol Histopathol 1997; 12: 319-36.
17. Otto WR. Lung epithelial stem cells. J Pathol 2002; 197: 527-35.
18. Edwards DR, Murphy G, Reynolds JJ et al. The Transforming growth factor-β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899-904.
19. Reiss M. TGF-β and cancer. Microbes Infect 1999; 1: 1327-47.
20. Kawakubo H, Brachtel E, Hayashida T et al. Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res 2006; 66: 7075-82.
21. Aoki T, Du Mori TX, Nisihira T, Matsubara T, Nakamura Y. Allelotype study of esophageal carcinoma. Genes Chromosomes Cancer 1994; 10: 177-82.
22. Sakata K, Tamura G, Nishizuka S et al. Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Genes Chromosomes Cancer 1997; 18: 318-21.
23. Ohgaki K, Iida A, Kasumi F et al. Mapping of a new target region of allelic loss to a 6-cM interval at 21q21 in primary breast cancers. Genes Chromosomes Cancer 1998; 23: 244-7.
24. Yamamoto N, Uzawa K, Yakushiji T, Shibahara T, Noma H, Tanzawa H. ANA lysis of the ANA gene as a candidate for the chromosome 21q oral cancer susceptibility locus. Br J Cancer 2001; 84: 754-9.
25. Melamed J, Kernizan S, Walden PD. Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 2002; 34: 28-32.
26. Ajima R, Akiyama T, Usui M et al. Osteoporotic bone formation in mice lacking tob 2; involvement of Tob2 in RANK ligand expression and osteoclasts differentiation. FEBS Lett 2008; 582: 1313-18.
27. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008; 123: 1-7.
28. Matsumoto S, Iwakawa R, Takahashi K et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007; 26: 5911-8.
29. Harada N, Maniwa Y, Yoshimura M et al. E1B-deleted adenovirus replicates in p53-deficient lung cancer cells due to the absence of apoptosis. Oncol Rep 2005; 14: 1555-63.
30. Ou YH, Chung PH, Hsu FF, Sun TP, Chang WY, Shieh SY. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J 2007; 26: 3968-80.
31. Prevot D, Morel A, Voeltzel T et al. Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: Involvement in estrogen receptor alpha signaling pathway. J Biol Chem 2001; 276: 9640-8.
32. Swiatkowska M, Pawlowska Z, Szemraj J, Drzewoski J, Watala C, Cierniewski CS. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity. Jpn J Pharmacol 2002; 90: 337-44.
33. Mauxion F, Faux C, Séraphin B. The BTG2 protein is a general activator of mRNA deadenylation. EMBO J 2008; 27: 1039-48.
34. Yoshida Y, Yoshida EH, Nakamura T, Yamamoto T. Association of ANA, a member of the antiproliferative Tob family proteins, with a Caf1 component of the CCR4 transcriptional regulatory complex. Jpn J Cancer Res 2001; 92: 592-6.
35. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis. Int J Cancer 1997; 72: 1-22.
36. Itoh T, Tanioka M, Yoshida H et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-51.
37. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-33.
38. Devy L, Blacher S, Grignet-Debrus C et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16: 147-54.
39. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dano K. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991; 51: 4067-71.
40. Kono S, Rao JS, Bruner JM, Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 1994; 53: 256-62.
41. Pederson H, Brunner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5.
42. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in Stage I-III lung carcinoma. Cancer Lett 2006; 236: 125-32.
43. Pappot H, Pedersoen AN, Brunner N, Christensen IJ. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: Relation to prognosis. Lung Cancer 2006; 51: 193-200.